confirmed RT-PCR for SAR-CoV-2 patients with asymptomatic or mild symptoms : Asymptomatic covid-19 patients, mild-symptom covid-19 patients, Ben-cha-lo-ka-wi-chian (Ha-rak), Juntaleela, Fatalaijone, Favipiravir, viral clearance
Conditions
Interventions
Thai recipes group will receive Ha-rak 1500 mg, Juntaleela 1500 mg and Fatalaijone 1500 mg PO QID on day 1 to day 5. ,Favipiravir group will receive Favipiravir treatment of 1800 mg PO BID on day 1, t
Experimental Drug,Active Comparator Drug
Thai recipes ,Favipiravir
Sponsors
Giving Mind Nirvana Soul Foundation
Eligibility
Sex/Gender
All
Age
20 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. 20 (minimum) - 60 years of age 2. Diagnosis of COVID-19 infection confirmed by RT-PCR test for SAR-CoV-2 3. Asymptomatic or mild COVID-19 symptoms: fever, cough, malaise or headache 4. No uncontrollable underlying disease 5. Onset of symptoms is within 5 days or positive RT-PCR for SAR-CoV-2 within 5 days 6. Signed informed consent provided by patient 7. Willing to stay at research site at least 6 days
Exclusion criteria
Exclusion criteria: 1. COVID19 positive based on Antigen test but PCR negative 2. Severe or critical clinical conditions (Glasgow coma scale less than 14) 3. Severe COVID-19 4. Patient who is on mechanical ventilator 5. Abnormal chest x-ray 6. Dyspnea or respiratory rate above 30 per minute 7. Hypoxia or oxygen saturation less than 96 percent 8. Underlying diseases including Diabetes mellitus, uncontrollable hypertension 9. Abnormal liver function test: ALT/AST increased 5 times higher than the upper limit of normal or with Child Pugh C 10. Renal failure or Creatinine clearance (Cockcroft-Gault Equation) less than 30 ml/min or having hemodialysis/peritoneal dialysis 11. Known allergy or hypersensitivity to Thai recipes 12. Pregnant (female of childbearing age with positive urine pregnancy test) or Lactating female
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of Viral clearance at day 7 day 7 Nasopharyngeal swab and RT-PCR for SAR-CoV-2 ,clinical improvement Every day from Day0 to Day7 or until discharge vital sign, symptoms, oxygen saturation | — |
Secondary
| Measure | Time frame |
|---|---|
| Viral clearance day 3, 5, 9, 13 or until result negative, Confirmed by RT-PCR Antigen test kit (ATK),ICU transfer rate any time point Number of patients who has been transferred to ICU,Mortality rate any time point Number of death,supplemental oxygen therapy requirement any time point number of patient who need oxygen therapy,ventilators requirement any time point number of patient who need ventilators,Safety assessment Day0 and day 7 Liver function test (AST, ALT, AP, Bilirubin)CBC, creatinine | — |
Countries
Thailand
Contacts
Public ContactPongsak Tangkana
Giving Mind Nirvana Soul Foundation
Outcome results
None listed